Thrombocytopenia
Conditions
Brief summary
The primary objective of the study is to measure platelet corrected count increments and the incidence of serious adverse events (SAE). The primary endpoint is the platelet corrected count increment measured 1-hour post transfusion in response to the infusion of platelet concentrates treated with the Mirasol PRT System device (test product) versus untreated (reference product).
Detailed description
The objective of the study is to determine if the MIRASOL Pathogen Reduction Technology (PRT) System for Platelets device performs safely and maintains adequate platelet performance in a clinical setting. This will be achieved by comparing the platelet corrected count increment measured 1 hour post transfusion and the incidence of serious adverse events in response to the infusion of platelet concentrates treated with the device (test product) versus untreated (reference product) in thrombocytopenic subjects requiring platelet transfusions. The performance, safety, and tolerability profile of the device will be further assessed by monitoring and comparing the incidence of discontinuations due to adverse events in relation to platelet transfusion up to 4 weeks after transfusion, including the incidence of transfusion associated infections, and the number and time between transfusions.
Interventions
DEVICEPathogen Reduction Technology
Sponsors
Terumo BCTbio
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female of age of 16 years or older * Women of Child Bearing Potential not pregnant * Subject must have signed and dated the Informed Consent form * Hospitalized, thrombocytopenic subjects and expected to receive at least two platelets transfusion
Exclusion criteria
* History of any hypersensitivity reaction to riboflavin or metabolites * History of refractoriness to platelet transfusions * Positive lymphocytotoxic antibody test * Active bleeding * Splenomegaly * Acute or chronic Disseminated Intravascular Coagulation * History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenia Purpura, or Haemolytic Uremic Syndrome * History or diagnosis of an autoimmune disease affecting haemostasis * History of solid organ transplants * Evidence of occlusive venous disease * Clinical signs of infection at the time of inclusion * Pregnant or lactating females * Chronic alcohol misuse * Use of prohibited medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The platelet corrected count increment measured 1 hour post transfusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of days between platelet transfusions during the period of the study. | — |
| The number of platelet transfusions per subject. | — |
| The number of platelets infused per subject. | — |
| The number of platelets used. | — |
| The frequency of refractoriness to platelet transfusion. | — |
| The platelet corrected count increment measured 24 hours post-transfusion. | — |
| The number of red blood cell transfusions during the study period. | — |
| The incidence of serious adverse events in relation to platelet transfusions. | — |
| The incidence of any adverse events in relation to platelet transfusions. | — |
| The occurrence of bleeding episodes. | — |
| In case of refractoriness, the evidence for neoantigen immunization against test product. | — |
Countries
France
Outcome results
None listed